A Compilation of WHO GMP Audit Points
|
|
- Dwain Boyd
- 6 years ago
- Views:
Transcription
1 A Compilation of WHO GMP Audit Points Collected from WHOPIR of 28 companies Part VIII of VIII Current article Part VIII Support QMS Prepared and Submitted By: Edited by : A. Jwalakanth B.Pharm, MBA (Aus) Student Diploma In GMP XIII th batch Insights Professional Management Academy, PUNE Atul Shirgaonkar Course Director Diploma In GMP Insights Professional Management Academy, PUNE
2 SUPPORT QMS Out of Specification Test Results Retraining was effected and recorded OOS results were evaluated and investigated in accordance with written procedure. OOS was closed within 30 days The procedure follows the conventional approach with sections on tracing assignable cause to laboratory error or production error. Details on sampling and re-sampling were given Selected reports were reviewed. In all cases the established cause was analyst s error The SOP on "Handling and investigation of out of specification (OOS) results plus the corresponding flow chart and the registers were reviewed OOS log for 2010: There was separate registration for raw materials, packaging materials, finished products and stability study. OOS results were evaluated and investigated in accordance with written procedure. OOS was closed within 30 days OOS results were evaluated and investigated in accordance with SOP"OOS investigation for raw material, finished product & stability study". OOS investigation flow chart and Check list were available. Time limit for closing out of OOS was specified - 30 calendar days Technology Transfer: Transfer of Technology was included in the change control programme. The transfer of one of the products one plant to other plant was well documented in a Change Control. Deviations: Deviations related to the production were documented in Batch Manufacturing Reports/Batch Packaging Reports (BMR/BPR). According with the SOP QA personnel checked the deviation and decided that either a full scale product failure investigation must be performed Deviation was defined as unplanned departure from an approved instruction or established standard or an unexpected observation Deviations were investigated on Risk based analysis Deviations were classified as planned and unplanned. Deviations were closed within 30 days. Deviations were trended monthly and yearly SOP for handling Deviations SOP on:"deviation handling". Deviations were classified as: 1. Planned deviation 2. Unplanned deviation 3. Major deviation 4. Minor deviation The deviations registers were reviewed to verify that all deviations were included in the PQR. The deviation report for the change in packaging location was inspected. The SOP for deviations didn't address trending of deviations, to identify areas of recurrent deviations for continuous improvement in identifying possible corrective actions to be taken to prevent recurrent deviations. Page 2 of 11
3 DEVIATION MANAGEMENT: Deviation management was described in sop Deviations were investigated in accordance with the check list Deviations were classified into three CR, MJ, MI Deviations were trended yearly Changes and deviations were listed in PQR Deviations and changes should be closed in 30 DAYS The source of API was listed in the PQR for export market, the source of packing material, and packing material specification numbers were not listed in PQR Deviation management was described in a written SOP and flow chart SOP for handling Deviations Deviations and related SOP & Registers according to year wise There were sections on impact analysis, retraining, trends, CAPAs. Close out was required within 7 days for a major incident and 15 for a minor Deviation on action to address drains that were found without water air-seal Trending of deviations A formal system for deviation management was described in writing. Deviations were re-corded also in the Manufacturing Instruction Records (MIR) and Packaging Instruction Re-cords (PIR). Deviations were classified as planned and unplanned. Deviations were closed within 30 days. Deviations were trended monthly and yearly Changes and deviations were listed in Annual Product Review, TRENDS were part of APR Deviations were recorded in Batch Manufacturing records (BMR) and Batch Packaging Records (BPR). Trending of deviations was carried out every six months. Deviation trends and Log bookwere reviewed and found to be satisfactory. SOP on Handling of Deviations. The selected examples reviewed included: Process validation: The prospective validation protocol/report for specific product was reviewed. The V blender was used for the original validation studies but was not available in Block F, however equivalent equipment for blending and tablet compression was available in Block F and used for manufacture. The certificate of equivalence of tablet compression machine and Equipment Equivalency protocol for tablet compression machines as well as Certificate of equivalence of V blenders and Equipment Equivalency protocol for V blender ere therefore reviewed and found to acceptable. The process validation report for specific product was also reviewed and the results indicated low RSD results indicating good reproducibility The source data were reviewed (chromatograms) and back calculations from the peak areas were checked for selected samples Validation was carried out for three batches manufactured for the local market. PERFORMACNE QUALIFICATION OR PROCESS VALIDATION BOTH ARE TREATED AS SAME There was a validation matrix for the key processes, systems and major equipment Process validation reports and links to batch documents Page 3 of 11
4 Process validation source data (samples, chromatograms) Assay (FPP): Specification reference was BP. BP method is potentiometric titration (BP 2010) while In-house method was HPLC method. The method was similar to the Ethambutol hydrochloride tablets assay according with USP 32 monograph. A protocol and report were reviewed briefly for the process validation. Focus was placed on key steps and stages of the production process, and source data. Source data were verified for the blending stage. Chromatograms and calculations were checked including electronically stored data. According to the source data, the %RSD should have been calculated but it was not. The sample analysis of Rifampicin took place over 16 hours. Hold time of Rifampicin samples was inspected as the company analysed samples over an extended period despite the recommendations in the USP. Pest control: There was a pest control system in operation and elaborated in an SOP. The service was Contracted to an outside company and a Technical Agreement were available. All visits were recorded and observations noted. The schedule included routine regular spraying Insectocutors was checked twice daily. Glue pads used to trap rodents were regularly checked and changed every three months SOP for preparation and use of Disinfectants (It specifies the preparation, concentration, validity (48 Hours) and rotation of disinfectants. Records of preparation of disinfectants were reviewed) Insect and rodent control procedure Didn't clearly identify the exact location of glue mates in receiving bay and warehouse area The location and frequency of the type of control used to be was defined. Measures used included Insectocutors, rodent baits and glue pads Pest control was managed by an outside contractor following a procedure, if defined location and frequency of the type of control used for insects (Fortnightly) and for rodents (fortnightly) There were insectocutor installation were managed using an SOP, these installation were the only internally placed pest controls allowed Self inspection procedures: This procedure was comprehensive and the check list used covered all areas of production, quality control, quality assurance and engineering Self inspection was carried out once in three months for all departments according to a written SOP and audit schedule. Audits were carried out by suitable trained, independent personnel from those departments what were subjects for audits The SOP for self inspection, together the plan and the report of implementation SOP on Self Inspection, Plans, Reports SOP on Self Inspection, Plans, Reports Self inspection was carried out every 6 months. Self inspection team was properly trained. Self inspection observations were classified as critical, major and minor After completion of self inspection, the self inspection report was drawn up and necessary CAPA were initiated. After the completion of CAPA the self inspection was closed out Observations were classified as three cr, mj, mi Self inspection schedule must be prepared The company had a basic self inspection program which consisted of semi-annual reviews Page 4 of 11
5 of all of its operations, and production activities. There was a standard operating procedure to cover the basic approach to self inspection, and an annexed set of checklists designed to cover different manufacturing activities in different areas. SELF INSPECTION AND QUALIT AUDIT: Self inspection was performed routinely, twice per year according to a written procedure. Reports were prepared and corrective actions were required. Proposed corrective actions were reviewed and approved. Implementation of corrective actions was controlled Self-inspection was documented, and there was an effective follow-up programme. Smoking, eating, drinking, chewing, and keeping plants, food, drink, smoking material and personal medicines was not be permitted in production, laboratory and storage areas, or in any Other areas where they might adversely influence product quality Questionnaires on GMP requirements and main GMP items were covered. After completion of self inspection, self inspection report was drawn up and necessary Corrective and preventive actions (CAPA's) were initiated. Implementation of CAPA s was monitored. Self inspection schedule was available for inspection. Self inspection was carried out every 6 months. Self inspection team was properly trained. Self inspection observations were classified as critical, major and minor regular continuous SOP training. Self inspection were carried out twice a year according to department wise Personnel administration features included: Training: Recruitment and training of personnel Safety Medical examination organization Laundry The induction training planner was given by the Human Resource department and other individual departments established their annual department training plans The company had had a comprehensive training program for all the employees. This was coordinated by QA but the concerned department head identified the training was identified based on experience, qualification, job assigned Attendance sheets for training sessions were available Training was of two types: 1. Basic Training: general discipline basics of GMP, Hygiene & Sanitization Safety entry/exit procedures 2. In-service training: Operating instruction of production machines, Job related Training (SOPs Training), maintenance of BMRs and GLP training Training evaluation was carried out by questionnaires, oral and written examinations and detailed audits of work performance. Retraining needs were identified through performance evaluation. Records of both Training as well as retraining was maintained Records maintained included Personnel Training Card and Training Log Book. Page 5 of 11
6 Effectiveness of Training was assessed by: TRAINING: Immediate evaluation of the personnel which was conducted after each training session by Questionnaire or by oral assessment. Long-term evaluation which was carried out by the concerned supervisor and training Coordinator. The concerned department head identified the retraining needs of the employees Based on their consecutive assessment and audit deficiencies. Any change in system or Procedures requires retraining Training (Induction and continuing), SOP plus records of Training for selected personnel Provision for trending of observations from self inspection reports The quality of the systems, procedures and products were regularly reviewed and monitored through an elaborate self inspection procedure and annual product review. New staff was given an orientation to the company and its Products and underwent basic training including health, hygiene and safety regulations, basics of GMP and statutory requirements. In-service training included operating instruction of production machines, Job related Training(SOPs Training), maintenance of BMRs and GLP training Retraining needs were identified through performance reviews, self-inspection and audits. Self inspection Corresponding correction reports Reports were provided to management for evaluation there was trending was observed Training records were maintained together with personnel files The overall training approach was specified in a written SOP. A training needs matrix was set up for each employee The attendance sheets for specified training were available. Training is to be given on-job training, external training, and continuous training, and training of new and revised procedures Training flow chart, training plan and program me for the year wise has to be prepared Training record on risk assessment (FMEA) for two employees The training needs were identified and training was organized as per SOP "Procedure for training of plant personnel". There were several types of training explained in the SOP. Training effectiveness was evaluated by the questions and multiple choice or True or False answers. SOP "Procedure for training and certification of analyst" was reviewed. For the analysts certification "Coded samples" were given to analyst and results were Compared against a key. Analyst's re-certification was carried out for all analysts once in two years Induction training is given to all staff by HR, and then introduced to all departments. A schedule is defined for the induction. On the job training is given; retraining is given as Needed and a certificate is issued after successful training. Assessment is done (generally) by questionnaire. Training needs are identified and a training schedule is defined. Training is given and assessment is done. Provision is made for re-training Induction training covers personnel, GMP, engineering, health and safety, security; QA etc. The training program for 2010 was reviewed. The records for February 2010 (including trainees) were requested. Several training records were reviewed. The training records revealed that the topics identified for training were covered. Questionnaires were in place for assessment after training in topics such as cgmp. Page 6 of 11
7 Training was done according to an annual schedule. The company had a comprehensive training program for all the employees. Training was divided into FIVE categories: 1. Induction 2. C GMP 3. CGLP 4. Job related SOP Training 5. Safety Health and Environment and specific Training Training certificates were issued after successful completion of training. If training was not successful, personnel had to be re-trained and re-evaluation had to be carried out. Persons engaged in manufacturing and QC operations had received comprehensive initial Training (induction programme) and on the job training covering their operational duties and GMP. Effectiveness of training was examined by written exam, but there was need to effectively monitor compliance with the policy on pass mark and retraining The concerned department head identified the training needs based on their assessment and job assigned to the employees Training procedures and records Training Information Management System was being used to schedule, record and evaluate the training needs Effectiveness of Training was assessed by: Immediate evaluation of the personnel which was conducted after each training session by questionnaire and oral assessment, retraining was given if the score was less than 70% Training of production officer who performed IPC counting of tablets Questionnaire that was used to assess the training of a production officer on FMEA Long-term evaluation which was carried out by the concerned supervisor and training coordinator. All employees were evaluated once in 6 months The concerned department head identified the retraining needs of the employees based on their consecutive assessment and audit deficiencies personnel receiving training should be supervised until they were trained in their respective areas The training programme for casual staff NOTE: Any change in the system or Procedure requires retraining PRODUCT RECALLS: The timelines to conclude the recalls (Class I within 2 days, Class II within 7 days and Class III within 15 days), composition of the recall committee and the parties to be informed while conducting a recall. SOP for Product Recall System accordingly year wise SOP for Product Recall System accordingly year wise In case there are no recalls, a mock recall should be carried out every three years according to the company SOP Training records and annual training plan were maintained Recall procedure was reviewed. Responsible person for the recall was Corporate QA. Corporate QA afterwards informed Unit QA Composition of the recall committee and the parties to be informed while conducting a recall Page 7 of 11
8 There was a procedure to conduct dummy recall at least once every two years in order to evaluate the effectiveness of the recall procedure Dummy recall validation report was reviewed and it covered only the domestic market. There were three recall levels specified: Level A Recall from the customers Level B Recall from all links in the distribution chain Level C Recall from certain links in the distribution chain Dummy recall Validation protocol/report "Dummy recall validation" was available for inspection and was found to be satisfactory. According with SOP Dummy recall should be revalidation once in two years if there was no recalls Recall was classified as CLASS 1, CLASS 2, and CLASS 3 and there is time limit according to class EX: CLASS 2 AND 3 is three business days Compliant Handling: Compliant Handling system (SOP + Registers for year wise) compliant register compliant investigation report sop for complaints: the sop detailed the procedure for handling, investigation, reporting and corrective action NOTE: The sop has to mention, if complaint of serious nature it has to report to national authority SOP for root cause analysis related to a complaint; There was a procedure for handling complaints. This ensured that complaints were registered, Investigated, corrective action was taken and feedback was given. This procedure was covered by an SOP The Responsible person for coordinating and processing the complaints was designated. Complaint investigation records were kept together with corresponding BMR. CAPAs were identified Ishikawa fish bone tool was used for the 95% of complaint investigation Complaints were classified as following: Complaints were classified as product quality complaints, product packaging complaints and medical complaints. Complaints were categorized as category I, II and III. Complaints were reviewed every 3 months A. Product Quality complains - category I B. Product packaging complaint - category II C. Medical complaints Category III. Serious medical complaints were reported to respective RA) Market complaint registers for 2008 and 2010 were checked and found acceptable The recall procedure was explained in the SOP "Product recall procedure" and the responsible person for handling of the recalls was QA Executive / Manager Complaints were categorized as: quality complaints, packaging complaints and adverse drug event complaints. Complaint trending was carried out every three months In case of the quality complaints other batches were checked in order to determine whether they are also affected Page 8 of 11
9 COMPLIANTS: Complaints were classified as Critical / Major / Minor and others were recorded in the complaint log books and market complaint list CAPA was generated for all critical and major complaints in accordance with written SOP The compliant investigation was completed within 30 days and if necessary a decision about recall will be taken according to SOP The investigation report of market complaints for specific products and trend analysis of market compliant and market compliant analysis for year wise reviewed Complaints has to be investigate according to ROOT CAUSE ANALYSIS, and SUITABLE CAPA were determined A matrix was available for the product complaint investigation referring to BMR, BPR review, analytical record review etc.. The inspectors reviewed complaint number XYZ Complaints: selected examples reviewed with no major issues. A complaint received by WHO-PQ related to the poor sealing of blisters of one product was presented to the company for investigation and an acknowledgement letter was received Complaints were categorized as category I, II and III. Complaints were reviewed every 3 months In case of the quality complaints other batches were checked in order to determine whether they are also affected Trending of Complaints: Complaint trending will be done once per year. COMPLIANT HANDLING PROCEDURE : The SOP on handling market complaints was reviewed. Complaints were classified as critical, major, minor and Adverse Drug Reaction The register for 2010 was issued by QA and included a complaint submitted by WHO about wrinkled blisters of Ethambutol/Isoniazid/Pyrazinamide/Rifampicin tablets 275/75/400/150mg. This was reviewed in detail covering BMR; vendor audit of the supplier of foil; sampling and testing of foil; storage, issuance and use of foils; in-process checks during packaging; the investigation report. A number of observations were made: a) It was noted that packaging was done using 6 rolls of leftover Aluminium foil, instead of 1 roll usually used. 3 out of the 9 PVC/PVDC rolls were also leftovers, significantly smaller than the normal full roll. b) There were no specific checks whenever a roll was changed and correct setting of the tension and alignment of the foil was only manually checked; no copy of the blister after change was kept with the BMR; frequency of leak test performed was not enough to capture problems during change of rolls. c) In leak test done for the blisters, the vacuum actually achieved was not systematically monitored or recorded. d) At the time, "wrinkling of blisters" was not listed among defects to look for during inspection of blisters and there was no SOP on AQL levels. A new SOP on AQL has been put in place listing wrinkling of a blister as minor defect, without assessing its possible indication of poor sealing leading to leakage. Page 9 of 11
10 d) These risks in packaging and inadequate in-process checks were not considered during investigation. It was therefore concluded that the weakness noted in the packaging, in-process testing and investigation could not give confidence that adequate QA procedures were in place during manufacturing. Holding time studies of cleaned equipment: MB analysis was performed to establish clean equipment holding time Audit report was written and corrective actions (CA) proposed. Implementation of CA was checked by the QA. SOP on the hold time for dispensed raw materials, in-process and finished. SOP on Hold time study and the following selected reports of hold time study protocols and Reports: a) Protocol for Binder holds time study. b) Protocol for Lubricated blends hold time study. c) Protocol for the Compressed tablets hold time study. d) Protocol and Report for blend hold time for one ARV product Protocol and Report for blend hold time for one ARV product conducted Holding time validation for granules and tablets According with validation report the holding time for granules was specified 45 days and for coated tablets 90 days. Holding time in between blending and compression was defined. There was a general SOP on Cleaning and storage and labeling of cleaned equipment. It specified the holding time for wrapped items to be 72 hours and unwrapped items to be 24 hours Holding time studies of cleaned equipment Validation report was reviewed. Holding time studies for the sifter was evaluated. According with validation protocol/report samples were taken every day for duration of 9 days Samples were taken using swab method. MB analysis was performed. Acceptance limit for microorganisms was specified. According with the results established holding time for cleaned equipment was specified 7 days. Calibration of Balances: Daily checking of analytical balances was carried out using two calibrated standard weights, fortnightly calibration was carried out using 6 calibrated standard weights,. Standard weights calibration certificates were presented to the inspectors It was discussed with the company that it would be necessary to specify on the label "clean before use" in case if the cleaning hold time has been exceeded. Production equipment and instrument calibration schedule and PM schedule were managed Page 10 of 11
11 by the SAP system Schedules to be Prepared: Equipment re-qualification schedule Preventive maintenance schedule for facilities and equipment Self inspection and schedule Stability study, annual stability schedule and monthly stability planner Various documents were reviewed such as: Layout of the site Organogram Quality Manual Change control SOP Different change control forms Lists of all products manufactured, with their marketing destination SOP for Annual Report Annual report for Forcan-150 (year 2008) Stability studies for particular product Daily checking of balances: Daily checking of analytical balances was carried out using 5 different calibrated Standard weights; monthly calibration was carried out using 11 weights. Standard Weights calibration certificates were presented to inspectors. Computer System: The company were requested to provide documentation to show that the system had been Validated and was operated in accordance with guidelines given in both the WHO GMP Publication and EU Orange Guide Page 11 of 11
Prequalification of Medicines Programme
Prequalification of Medicines Programme SOP 408.4 Annex A WHO PUBLIC INSPECTION REPORT Finished Product Manufacturer WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General
More informationPrequalification of Medicines Programme
Prequalification of Medicines Programme SOP 408.4 Annex A WHO PUBLIC INSPECTION REPORT Finished Product Manufacturer WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General
More informationPrequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Tablets
Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: information about the inspection Name of manufacturer Physical address production departments
More informationA Compilation of WHO GMP Audit Points
A Compilation of WHO GMP Audit Points Collected from WHOPIR of 28 companies Part IV of VIII Current article Part IV Quality Systems Prepared and Submitted By: Edited by : A. Jwalakanth B.Pharm, MBA (Aus)
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer
Prequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer PART 1: GENERAL INFORMATION Name of Manufacturer Calyx Chemicals & Pharmaceuticals Ltd Unit:
More informationA Compilation of WHO GMP Audit Points
A Compilation of WHO GMP Audit Points Collected from WHOPIR of 28 companies Part III of VIII Current article Part III Production Prepared and Submitted By: Edited by : A. Jwalakanth B.Pharm, MBA (Aus)
More informationPrequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer
Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT API Manufacturer WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer Part 1: General information Name of Manufacture Unit number
More informationPrequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer
Prequalification of Medicines Programme SOP 408.4 Annex B WHO PUBLIC INSPECTION REPORT API Manufacturer Part 1: General information Name of Manufacturer Unit number WHO PUBLIC INSPECTION REPORT (WHOPIR)
More informationIntroduction to Medicines Inspections Technical Updates:
Introduction to Medicines Inspections Technical Updates: GMP inspections of Active Pharmaceutical Ingrédients and Finished Pharmaceutical Products (including Reproductive Health Products) Vimal Sachdeva,
More informationSupersedes Division Name Revision No. 0 Export Division Page No. 1 of 9
Page No. 1 of 9 Control Status 1.0 Purpose To lay down a procedure for conducting GMP inspection and report writing for issue of Written Confirmation for for medicinal products for human. 2.0 Scope This
More informationAnnex 4. Guidance on good manufacturing practices: inspection report. Background
Annex 4 Guidance on good manufacturing practices: inspection report Background The need for revision of the Guidance on good manufacturing practices: inspection report (World Health Organization (WHO)
More informationSITE MASTER FILE For MHRA
ABC CO., LTD. For MHRA Prepared by Date Approved by Date Verified by Date Document No.: SMF, Version No: 01, Effective Date: 09/05/06 Document No.: SMF Version No.: 01 Effective Date: 09/05/06 Page 2 of
More informationWHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Mylan Nashik ( Sinnar in CRM) AND
SOP 408.4 Annex D 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer
Prequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer PART 1: GENERAL INFORMATION Name of Manufacturer Shanghai Shyndec Pharmaceutical (Haimen)
More informationGMP Requirements. Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP)
GMP Requirements Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP) 2016. ALL RIGHTS RESERVED. Outline GMP Procedures and standards
More informationPrequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General information
Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General information Name of Manufacturer M/s. Hetero Labs Limited Unit number Production
More informationGuidelines for Process Validation of Pharmaceutical Dosage Forms
Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical
More informationPrequalification Team Inspection services WHO INSPECTION REPORT of the FPP manufacturer
Prequalification Team Inspection services WHO INSPECTION REPORT of the FPP manufacturer Part 1 Manufacturers details Company information Name of manufacturer Corporate address of manufacturer Contact person
More informationGMP The Other Side of Chemistry, Manufacturing & Controls (CMC)
Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls
More informationLessons from Pharmaceutical Laboratory related FDA Warning Letters
Lessons from Pharmaceutical Laboratory related FDA Warning Letters The Agilent Critical Compliance Seminar 2016 Ludwig Huber Ludwig_huber@labcompliance.com Overview FDA Inspections and reports GMP compliance
More informationWHO PUBLIC INSPECTION REPORT (WHOPIR) of the FPP manufacturer
WHO PUBLIC INSPECTION REPORT (WHOPIR) of the FPP manufacturer Part 1: General information about the inspection Name of manufacturer Meditab Specialities Pvt. Ltd. Physical /postal address J-4/2 Additional
More informationInspection. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory
More informationGood manufacturing practices
ORIGINAL PAPER 1AR-10 ISBT Science Series (2009) 4, 6 10 Journal compilation 2009 International Society of Blood Transfusion Good manufacturing practices Blackwell Publishing Ltd A. Ahmed Quality Manager,
More information18.H Questionnaire for preparing GMP-inspections
Questionnaire for preparing -inspections Questionnaire for preparing -inspections Here you will find answers to the following questions: What questions are typically asked during inspections based on current
More informationDECEMBER 2008 GUIDANCE NOTES ON PRODUCT QUALITY REVIEW
DECEMBER 2008 GUIDANCE NOTES ON PRODUCT QUALITY REVIEW 1.0 INTRODUCTION: The purpose of this guidance is to communicate the expectation with regard to the conduct of Product Quality Review. Product Quality
More informationConducting Supplier Audits: Ensure Validation Compliance
Conducting Supplier Audits: Ensure Validation Compliance Presented by: Gamal Amer, Ph. D. Principal Premier Compliance Services, Inc. All rights reserved. Do not copy without permission. 1 Outline Why
More informationPrequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer
Prequalification of Medicines Programme SOP 408.4 Annex B WHO PUBLIC INSPECTION REPORT API Manufacturer Part 1 General information Name of Manufacturer Unit number WHO PUBLIC INSPECTION REPORT (WHOPIR)
More informationDrug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel
Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active
More informationProduct Quality Review: Overview and Feedback from Inspection
Product Quality Review: Overview and Feedback from Inspection GMP/Market Compliance Information Day October 23 rd 2008 Lorraine Nolan Acting Inspection Manager IMB Slide 1 Scope of Presentation Overview
More informationDocumenta tion and Records
Documenta tion and Records Page 1 of 30 Training Outcome of the Module: After completing this module, you will be able to: Recognize the importance of procedures Recognize the importance of record keeping
More informationQuality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines
Human Journals Review Article January 2017 Vol.:8, Issue:2 All rights are reserved by Chagi Venkatesh et al. Quality Assurance in Pharmaceutical Biotech Industries as Per Regulatory Guidelines Keywords:
More informationGMP On Site Series. GMP Essentials
GMP On Site Series GMP Essentials GMP Basics Objectives 1. State the critical definitions of the pharmaceutical industry. 2. Describe the law as it applies to various critical functions. 3. State the history
More informationPrequalification Team Inspection services WHO PUBLICK INSPECTION REPORT of the FPP manufacturer
Prequalification Team Inspection services WHO PUBLICK INSPECTION REPORT of the FPP manufacturer Part 1 General information Manufacturers details Company information Name of Anhui Biochem Bio-pharmaceutical
More informationTechnical updates medicines inspections: Finished Pharmaceutical Products (FPP)
Technical updates medicines inspections: Finished Pharmaceutical Products (FPP) Vimal Sachdeva, Technical Officer (Inspector) WHO Prequalification Team (PQT), WHO/HIS/EMP/RHT 20 Avenue Appia, CH - 1211,
More informationThe World Bank. Aide Memoire for use during GMP inspections
The World Bank e for use during GMP inspections The World Bank Procurement of Health Sector Goods Contact persons: 0 1. General information about the manufacturer Name of manufacturer Physical address
More informationContents. Contents (13) 1 Production (23)
1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing
More informationUNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products
UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products UNICEF Industry Consultation with Manufacturers and Suppliers of Finished Pharmaceutical Products 29 th 30 th September
More informationInspection Hot Topics
Inspection Hot Topics QP Forum, Trinity College Ciara Turley, Inspector, HPRA 16 th April 2015 Content Hot topics = common deficiencies Data based on 100 inspections conducted in 2014 Inspections of non-sterile
More informationCommon deficiencies/ hot topics
Common deficiencies/ hot topics Non-sterile & API manufacture Oisín Daly GMP Conference 7 February 2017 Dublin Non-sterile finished product manufacture Deficiencies by Eudralex Vol. 4 GMP guide > 60% 3
More informationGood Manufacturing Practices Purpose and Principles of GMP. Tony Gould
Good Manufacturing Practices Purpose and Principles of GMP Tony Gould Why GMP? Provides a high level assurance that medicines are manufactured in a way that ensures their safety, efficacy and quality Medicines
More informationHACCP audit checklist
Requirement HACCP audit checklist Prerequisite Program Management Commitment 1. Senior management ensures that the responsibilities and authorities are defined and communicated within the company Internal
More informationProduct quality reviews
Product quality reviews Document valid from: 07.11.2017 Document number: I-SMI.TI.14 Version no. 05 Classification: Public Replaced document: I-SMI.TI.14_04 dated: 14.08.2014 Root QMI documents: - Referenced
More informationStrategies to Revise Quality Policy and Quality Objectives. Eileen Cortes February 22, 2017
Strategies to Revise Quality Policy and Quality Objectives Eileen Cortes February 22, 2017 Agenda Elements of Compliance Quality Policy Outline Quality Strategy and Objectives Case Study Open Discussion
More informationCOMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS
COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance
More information1.2. Timelines Batch Record comments must be documented immediately when event occurs.
Standard Operating Procedure Title: Quality Concerns Investigation Process Table of Contents 1. Batch Record Comments... 2 2. Deviation Report (DR)... 2 3. Cross Functional Investigations (CFI)... 3 4.
More informationWHO PUBLIC INSPECTION REPORT (WHOPIR) of the API manufacturer. India
WHO PUBLIC INSPECTION REPORT (WHOPIR) of the API manufacturer Part 1: General information about the inspection Name of manufacturer IPCA Laboratories Ltd. Indore, India Physical address: Plot No 89A-B/90/91
More informationV. S. International Pvt. Ltd
V. S. International Pvt. Ltd Innovation in medicine Partners In human care for today and tomorrow... Unit I - Daman V. S. International is a Healthcare Company with it s Corporate Head office at Mumbai,
More informationWARNING LETTER AUG 3, 2016
Ropack, Inc. 8/3/16 Department of Health and Human Services Public Health Service Food and Drug Administration 10903 New Hampshire Avenue White Oak Building 66 Silver Spring, MD 20993 WARNING LETTER AUG
More informationPrequalification Team Inspection services WHO INSPECTION REPORT of the FPP manufacturer
Part 1 Manufacturers Details Company information Name of manufacturer Corporate address of manufacturer Contact person Inspected site Address of inspected manufacturing site if different from that given
More informationPROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT
August 2010 RESTRICTED PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT Please address any comments on this draft guideline
More informationWHO GMP for Pharmaceutical Products: Main Principles
제약업계의품질경영 : 원칙과필수요소 (Quality management in the medicines industry: philosophy and essential elements) 1 In the medicines industry at large, quality management is usually defined as the aspect of the management
More informationQuality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines
Quality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines Longe Sunday Anthony Head- Quality Assurance May & Baker Nigeria Plc. Pharmacentre, Ota, Nigeria eaglesconsult@gmail.com; Slonge@may-
More informationThe EDQM Inspection Programme
The EDQM Inspection Programme Prague, 20 September 2017 Dr Sotirios Paraschos, Inspector Certification of Substances Department, EDQM Overview: EDQM Inspection Programme in the frame of Certification Procedure
More informationPrequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer
Prequalification of Medicines Programme SOP 408.4 Annex B WHO PUBLIC INSPECTION REPORT API Manufacturer Part 1: General information Name of Manufacturer Unit number WHO PUBLIC INSPECTION REPORT (WHOPIR)
More informationQMS CO-ORDINATOR & GENERAL PROCEDURES:-
1. QMS CO-ORDINATOR & GENERAL PROCEDURES:- (1) How do you measure effectiveness of system for working of your company? How do you collect necessary information for the same? Are you getting information
More informationCUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions)
21 CFR Part 11 FAQ (Frequently Asked Questions) Customer and Supplier Roles and Responsibilities for Assessment of METTLER TOLEDO STARe Software Version 16.00, including: - 21 CFR 11 Compliance software
More informationLibrary Guide: Active Pharmaceutical
Library Guide: Active Pharmaceutical Ingredients (API) Table of Contents Overview...3 Sample Curriculum...5 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)...7 A Tour of the
More informationWHO guidelines on quality risk management
Annex 2 WHO guidelines on quality risk management 1. Introduction 62 1.1 Background and scope 62 1.2 Principles of quality risk management 64 2. Glossary 67 3. Quality risk management process 70 3.1 Initiating
More informationSESSION 14. Documentation Requirements and Management for Validation. 30 March Frits Vogt
Validation Services SESSION 14 Documentation Requirements and Management for Validation 30 March 2017 Frits Vogt fritsvogt@valserv.nl Content Documentation Requirements and Management for Validation I.
More informationWholesaling & Distribution & the GMPs
Wholesaling & Distribution & the GMPs Presented by Bryan Wright 11 th July 2016 Overview Wholesaling & distribution of Medicines (FPs) in the EU New EU GDP Guidelines Expectations How complicated can the
More informationWholesaling & Distribution & the GMPs
Wholesaling & Distribution & the GMPs Presented by Bryan Wright 11 th July 2016 Overview Wholesaling & distribution of Medicines (FPs) in the EU New EU GDP Guidelines Expectations How complicated can the
More informationTrotz sorgfältiger inhaltlicher Prüfung übernehmen wir keine Haftung für die Richtigkeit und Aktualität für Unterlagen von Dritten.
Trotz sorgfältiger inhaltlicher Prüfung übernehmen wir keine Haftung für die Richtigkeit und Aktualität für Unterlagen von Dritten. IFS HPC Issue 2 Joachim Mehnert Technical Director DQS CFS GmbH 23. February
More informationMost Common Deficiencies Found. Dr Florence Benoit-Guyod Head of the inspection section Certification of Substances Department
Most Common Deficiencies Found by EDQM Dr Florence Benoit-Guyod Head of the inspection section Certification of Substances Department Overview Fact & Figures Main deficiencies Conclusion 2 Inspection figures
More informationStandard Operating Procedure Title: Manufacturing Instruction For Tablet Packing
Form-560 Test and Retention Sample Log Book QMS-020 Documentation Rule for GMP Documents QMS-035 Deviation Report System QMS-090 Example-Evaluation of Batch Documentation for Tablet Packing WAR-075 Example-Tablet
More informationWebinar Expert Module 3: GMP Inspections Dupont
Webinar Expert Module 3: GMP Inspections Dupont 26 January & 9 February 2018 GOP-Innovations your Partner for Practical Training and e-learning Milenko Pavičić Pharmaceutical microbiologist, trainer, coach
More informationPolestar Power Industries (Pharma Division) Pioneer Manufacturer Of Beta-Lactum & Cephalosporin
Polestar Power Industries (Pharma Division) Pioneer Manufacturer Of Beta-Lactum & Cephalosporin R Polestar Power Industries (Pharma Division) Vill. Damuwala, Haripur Road, Barotiwala, Tehsi l Baddi, Distt.
More information2014 IPA / EDQM 4 TH TECHNICAL CONFERENCE QUALITY OF PHARMACEUTICAL INGREDIENTS. September 15,
2014 IPA / EDQM 4 TH TECHNICAL CONFERENCE QUALITY OF PHARMACEUTICAL INGREDIENTS - APPLYING LEARNINGS TO PRACTICE September 15, 2014 1 CONTENTS INTRODUCTION PRESENT STATE OF PHARMACEUTICAL INDUSTRY MANUFCTURING
More informationMASTER PLANNING FOR VALIDATION
MASTER PLANNING FOR VALIDATION By: Gamal Amer, Ph.D. Principal, Premier Compliance Services, Inc. 1 Process Validation: General Principles and Practices Guidance to industry issued by the FDA in January
More informationInternational Procurement and supply Schemes Part II
International Procurement and supply Schemes Part II by Dr. Nora Dellepiane Workshop: Global Registra8on and Vaccine Shortage Taipei, Taiwan 6 to 10 March 2017 Outline of the presentation Vaccine Supply
More informationSelf-Evaluation/Audit Checklist for Food Supplement Manufacturers
Self-Evaluation/Audit Checklist for Food Supplement Manufacturers This checklist has been developed by the EHPM quality working group. It combines work carried out by EHPM various national associations
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 8 Inspections, Compliance, Enforcement, and Criminal Investigations Lupin Limited 5/7/09 Department of Health and Human Services Public Health Service Food and Drug Administration CENTER FOR
More informationJournal of Chemical and Pharmaceutical Research
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(6):88-98 Conduct of Inspections for Pharmaceutical Manufactures
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationInspection of API Manufacturers & Update on Registration Process
Inspection of API Manufacturers & Update on Registration Process Catherine Neary, GMP Inspector GMP Conference 7 February 2017 Dublin Presentation Contents HPRA Inspection Programme for API Manufacturers
More informationGUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PH 1/97 (Rev. 3), 15 January 2002 ANNEX 15 QUALIFICATION AND
More informationCompliance with the GMP Standard in the International Level
Compliance with the GMP Standard in the International Level 27 th August 2018 Chandrashekar Ranga Deputy Drugs Controller (India) CDSCO (HQ) 1 Outline Provisions under the Drugs and Cosmetics Act, 1940
More informationGMP & Quality Assurance. Mayur Sushir Dept of Microbiology MJC
GMP & Quality Assurance Mayur Sushir Dept of Microbiology MJC Introduction GMP ensures that quality is built into the organization & processes involved in manufacture GMP covers all aspects of manufacture
More informationValidation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH)
Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH) *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY!
More informationQUALITY MANUAL ECO# REVISION DATE MGR QA A 2/25/2008 R.Clement J.Haislip B 6/17/2008 T.Finneran J.Haislip
UHV SPUTTERING INC Page 1 of 18 ECO REVISION HISTORY ECO# REVISION DATE MGR QA 1001 A 2/25/2008 R.Clement J.Haislip 1017 B 6/17/2008 T.Finneran J.Haislip 1071 C 1/13/2011 R.Clement J.Haislip 1078 D 5/15/2013
More informationDeficiencies found in Inspections and QP Responsibilities
Deficiencies found in Inspections and QP Responsibilities Ciara Turley, HPRA Inspector QP Forum, Trinity College, Dublin 25 th April 2017 Dublin Key QP Responsibilities Chapter 1, 1.4 (xv) Medicinal products
More informationThe APIC Audit Programme Version 5, July 2017
The APIC Audit Programme Version 5, July 2017 Table of contents 1 General 2. APIC Audit Programme 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification
More informationQUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION
PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PS/W 1/2011 2 Annexes 22 July 2011 QUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION PIC/S 2011 Reproduction
More informationControl Strategy. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 Control Strategy International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Introduction Structure of this session
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer
Prequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer PART 1: GENERAL INFORMATION Name of Manufacturer MSN Pharmachem Private Limited Unit Production
More informationDecember Dr. Abidi Pharmaceuticals
December 2016 Dr. Abidi Pharmaceuticals Abidi Evolution & Development in the past 70 years 1946 Established the First Private Pharmaceutical Company in Iran 1958 Received First License of Drug Manufacturing
More informationA Compilation of WHO GMP Audit Points
A Compilation of WHO GMP Audit Points Collected from WHOPIR of 28 companies Part VII of VIII Current article Part VII Quality Control Prepared and Submitted By: Edited by : A. Jwalakanth B.Pharm, MBA (Aus)
More informationIndustry Perspective on Manufacturing in Early Development
Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical
More informationNew GMPs for Active Substances & Excipients. Presented by Eoin Hanley 4 July, 2016
New GMPs for Active Substances & Excipients Presented by Eoin Hanley 4 July, 2016 What we will cover in this session The changing landscape EC Guideline on principles of GDP of active substances Formalised
More informationData Collection Tools Functions, Indicators & Sub-Indicators
Data Collection Tools 27- Functions, Indicators & A. National regulatory system Indicator RS1: Legal framework for establishment of a regulatory system, mandate and enforcement power for each function
More informationAugust 11, 2005 VIA FEDERAL EXPRESS
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Atlanta District Offke _ G 5 (/ k r) r.;%~ 6fl Sth Street, N.E. Atlsntx, Georgla 30304 August 11, 2005 VIA FEDERAL EXPRESS Dushyant
More informationSQF 2000 Food Safety Management System Implementation Workbook
This comprehensive SQF 2000 Food Safety and Quality Management System package contains everything you will need to achieve SQF 2000 Certification. We have written this workbook to assist in the implementation
More informationMEASURE FOR MEASURE: QUALITY METRICS
MEASURE FOR MEASURE: QUALITY METRICS PDA Midwest Chapter Dinner Meeting, Northbrook, IL-9 November 2017 Felicia Ford-Rice, Director, Strategic Compliance 2017 PAREXEL INTERNATIONAL CORP. AGENDA Robust
More informationUNICEF Quality Assurance in the procurement of medicines
UNICEF Quality Assurance in the procurement of medicines Peter S. Jakobsen October 2008 Quality Assurance Centre SUPPLY DIVISION 2 Today s presentation addresses 3 questions: How do UNICEF manage quality
More informationSubpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.
FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis
More informationPrequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer
Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1 Manufacturers details Company information Name of manufacturer Corporate address of
More informationSTANDARD OPERATING PROCEDURE TEAM INSPECTIONS
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 031-1 Annex 29 July 2009 STANDARD OPERATING PROCEDURE TEAM INSPECTIONS PIC/S July 2009 Reproduction prohibited for
More informationPharmaceutical Reference Standards: Overview and Role in Global Harmonization
Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference
More informationPrimusLabs.com Facility Audit Paperwork Checklist
PrimusLabs.com Facility Audit Paperwork Checklist v5.06 Audits Rev 3 Oct05 Please have the following paperwork available for the audit. The following list is a guide only and represents the minimum requirements
More informationQuality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals
Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality
More information